Trials / Unknown
UnknownNCT04447573
Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is aimed to evaluate the safety, feasibility and efficacy of BCMA CAR-T in the treatment of relapsed or refractory multiple myeloma
Detailed description
This is a study to evaluate the safety, feasibility and efficacy of BCMA CAR-T in the treatment of relapsed or refractory multiple myeloma. The Main research objectives: To evaluate the safety and efficacy of BCMA CAR-T in patients with relapsed or refractory multiple myeloma The Secondary research objectives: To investigate the cytokinetic characteristics of BCMA CAR-T in patients with relapsed or refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BCMA CAR-T | Biological: BCMA CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis; |
Timeline
- Start date
- 2020-06-30
- Primary completion
- 2022-08-30
- Completion
- 2022-12-30
- First posted
- 2020-06-25
- Last updated
- 2020-09-29
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04447573. Inclusion in this directory is not an endorsement.